Latest Content

Clinicians explore the complex relationship between ADHD medication and pregnancy, emphasizing individualized risk assessments for optimal maternal and child health.

A groundbreaking online ADHD assessment shows 78% agreement with clinician evaluations, enhancing access to mental health care for adults.

Seltorexant shows promise as a safe adjunctive treatment for patients with major depressive disorder and insomnia symptoms, with fewer weight changes than quetiapine XR.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Explore the emerging role of lifestyle interventions in psychiatry, enhancing patient care through nutrition and physical activity for mental health.

New research reveals midlife ADHD patients exhibit early Alzheimer disease biomarkers.

New data reveals Caplyta significantly improves remission rates in adults with major depressive disorder, offering hope for lasting relief from symptoms.

Centanafadine demonstrates promising effects on ADHD symptoms, enhancing key neurotransmitters without increasing psychomotor activity, according to poster data.

Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs.

A clinician shares her journey as a 3-time suicide survivor, advocating for vulnerability and compassion in mental health care.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

Psychiatrists explore the mental health impacts of protests, emphasizing the need for community support and ethical responsibility in turbulent times.

Explore groundbreaking insights from the 2025 Southern Florida Psychiatry Conference, covering VNS for depression, stuttering management, and postpartum care.